Clinical Trial Record

Return to Clinical Trials

Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention


2023-04-14


2025-10-31


2027-10-31


205

Study Overview

Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention

This is a community-based study requiring participant-self-enrollment, that can help to increase the rates of genetic testing among the family members of people who have been diagnosed with a hereditary cancer syndrome. The two main factors in this study are the IGNITE-TX intervention (website and navigator) and the free genetic counseling and testing. The IGNITE-TX Intervention is an innovative multi-modal intervention, with two components: a) interactive web "IGNITE-TX Hub" and b) genetic family navigators.

Primary Objectives: The primary objectives of this study are to assess the study feasibility by estimating: 1. The enrollment of probands and (ARRs) at-risk relatives over a 6-month period 2. The response rate to baseline and follow-up surveys by probands 3. The response rate to baseline and follow-up surveys by (ARRs) at-risk relatives Secondary Objectives: The secondary objectives of this study are to: 1. Measure (ARR) at-risk relatives completion of (CGT) cascade genetic testing among different study arms. 2. Measure the proportion of enrolled (ARRs) at-risk relatives who make an informed decision about (CGT) cascade genetic testing. 3. Measure the (ARR) at-risk relatives readiness for (CGT) cascade genetic testing 4. Measure proband and (ARR) at-risk relatives change in genetics knowledge 5. Measure proband readiness to communicate results of genetic testing with (ARR) at-risk relatives Secondary objectives in this feasibility study will be primary objectives in a larger study. This feasibility study is not powered to assess these objectives. Including them in this feasibility study will allow for assessment of our measurement tools (surveys from primary objectives) and offer insight into how the intervention may impact cascade genetic testing when implemented on a larger scale Exploratory Objectives: The exploratory objectives in this study are to estimate: 1. The average website traffic of the IGNITE-TX "Hub" and module completion 2. The average utilization of family genetic navigators by participants 3. Estimate the intra-familial correlation (IFC) for (ARR) at-risk relatives completion of (CGT) cascade genetic testing 4. Assess satisfaction with IGNITE-TX website modules and genetic navigator The exploratory objectives will allow for further evaluation of the IGNITE-TX website modules and navigator and understand how families with multiple (ARR)at-risk relatives respond to the intervention.

  • Gynecologic Cancer
  • Ovary Cancer
  • Pancreatic Cancer
  • Breast Cancer
  • Lynch Syndrome
  • Hereditary Breast and Ovarian Cancer Syndrome
  • Colon Cancer
  • Endometrial Cancer
  • Uterus Cancer
  • BEHAVIORAL: Free genetic testing and counseling group
  • BEHAVIORAL: IGNITE-TX Group
  • BEHAVIORAL: IGNITE-TX and free genetic testing and counseling group
  • 2022-0712
  • FP00015533 (OTHER_GRANT Identifier) (OTHER_GRANT: Foundation for Women's Cancer)
  • NCI-2022-10573 (OTHER Identifier) (OTHER: NCI-CTRP Clinical Trials Registry)

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2022-12-14  

N/A  

2025-09-04  

2023-01-05  

N/A  

2025-09-08  

2023-01-10  

N/A  

2025-09  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Health Services Research


Allocation:
Randomized


Interventional Model:
Factorial


Masking:
None


Arms and Interventions

Participant Group/ArmIntervention/Treatment
NO_INTERVENTION: Group 1 (Standard of Care Group)

Participants (probands, those with a hereditary cancer syndrome) are sent a family letter to share with relatives. The letter contains information about hereditary cancer syndromes and encourages relatives to participate in the study and to get genetic te

EXPERIMENTAL: Group 2 (Free genetic testing and counseling group)

Enrolled relatives will receive a letter and baseline survey with information to contact the tele-genetics company to arrange free genetic counseling and testing. This letter will be given to the relatives directly by the study

BEHAVIORAL: Free genetic testing and counseling group

  • Option to access no-cost telegenetic counseling and genetic testing

BEHAVIORAL: IGNITE-TX Group

  • Access online educational materials through the IGNITE-TX platform and receive assistance from a family genetic navigator

BEHAVIORAL: IGNITE-TX and free genetic testing and counseling group

  • Option to access no-cost telegenetic counseling and genetic testing, access to online educational materials through the IGNITE-TX platform, and assistance from a family genetic navigator
EXPERIMENTAL: Group 3 (IGNITE-TX Group)

Relatives of probands randomized to the IGNITE-TX intervention will receive a family letter after enrollment and baseline survey with their personal access codes (not to be shared) to the IGNITE-TX "Hub" (access online educational material through a platf

BEHAVIORAL: Free genetic testing and counseling group

  • Option to access no-cost telegenetic counseling and genetic testing

BEHAVIORAL: IGNITE-TX Group

  • Access online educational materials through the IGNITE-TX platform and receive assistance from a family genetic navigator

BEHAVIORAL: IGNITE-TX and free genetic testing and counseling group

  • Option to access no-cost telegenetic counseling and genetic testing, access to online educational materials through the IGNITE-TX platform, and assistance from a family genetic navigator
EXPERIMENTAL: Group 4 (IGNITE-TX and free genetic testing and counseling group)

Relatives randomized to this arm will receive a family letter after enrollment and baseline survey with their personal access codes (not to be shared) to the IGNITE-TX "Hub" (access online educational material through a platform) and information to contac

BEHAVIORAL: Free genetic testing and counseling group

  • Option to access no-cost telegenetic counseling and genetic testing

BEHAVIORAL: IGNITE-TX Group

  • Access online educational materials through the IGNITE-TX platform and receive assistance from a family genetic navigator

BEHAVIORAL: IGNITE-TX and free genetic testing and counseling group

  • Option to access no-cost telegenetic counseling and genetic testing, access to online educational materials through the IGNITE-TX platform, and assistance from a family genetic navigator
Primary Outcome MeasuresMeasure DescriptionTime Frame
Measure enrollment of probands and at-risk relatives over a 6-month periodUp to 6 months
Measure response rate to baseline and follow-up surveys by probands and at-risk relativesUp to 6 months
Secondary Outcome MeasuresMeasure DescriptionTime Frame

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Probands
    Inclusion Criteria:
    1. 18 years of age or older 2. Speaks and/or reads English or Spanish 3. Has known deleterious/pathogenic mutation or suspected deleterious/pathogenic variant in BRCA1 or BRCA2 (HBOC) or MLH1, MSH2, MSH6, PMS2, or EPCAM (LS) 4. Has access to the internet or phone and can send and receive email and/or text messages at a US telephone number 5. Has at least one at-risk relative who meets inclusion criteria for first-degree relative
    Exclusion Criteria:
    1. Has no at-risk relatives meeting inclusion criteria 2. Has negative germline genetic testing or only variant of uncertain significance 3. Unwilling or unable to provide consent 4.2. AT-RISK RELATIVES (ARR)
    Inclusion Criteria:
    1. 18 years of age or older 2. Speaks and reads English or Spanish 3. Resides in the United States 4. Can provide proof of deleterious/suspected deleterious HBOC or LS variant present in a first degree relative (biological mother or father, biological child, or full sibling) 5. Has access to internet or phone and can send and receive email and/or text messages at a US telephone number
    Exclusion Criteria:
    1. Unwilling or unable to provide consent 2. Reports no known HBOC or LS variant within the family 3. Has already been tested for the variant identified in the proband 4. Already listed as an ARR for another proband

Collaborators and Investigators

This is where you will find people and organizations involved with this study.


    • PRINCIPAL_INVESTIGATOR: Jose Rauh-Hain, MD,MPH, M.D. Anderson Cancer Center

    Publications

    The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

    General Publications

    No publications available